Optimal planning strategy among various arc arrangements for prostate stereotactic body radiotherapy with volumetric modulated arc therapy technique

Sang Won Kang; Jin Beom Chung; Jae Sung Kim; In Ah Kim; Keun Yong Eom; Changhoon Song; Jeong Woo Lee; Jin Young Kim; Tae Suk Suh

Uneingeschränkter Zugang

Optimal planning strategy among various arc arrangements for prostate stereotactic body radiotherapy with volumetric modulated arc therapy technique

und

| 15. Jan. 2017

Radiology and Oncology

Band 51 (2017): Heft 1 (March 2017)

Über diesen Artikel

Vorheriger Artikel

Nächster Artikel

Zitieren

Article Category: Research Article

Online veröffentlicht: 15. Jan. 2017

Seitenbereich: 112 - 120

Eingereicht: 19. Juli 2016

Akzeptiert: 25. Okt. 2016

DOI: https://doi.org/10.1515/raon-2017-0005

© 2017 Sang Won Kang, Jin Beom Chung, Jae Sung Kim, In Ah Kim, Keun Yong Eom, Changhoon Song, Jeong Woo Lee, Jin Young Kim, Tae Suk Suh

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

An arrangement of (A) one full arc (1FA), (B) one partial arc (1PA), (C) two full arcs (2FA), and (D) two partial arcs (2PA) in prostate SBRT-VMAT for the same patient.

An example of the dose distributions achieved with (A) one full arc (1FA), (B) one partial arc (1PA), (C) two full arcs (2FA), and (D) two partial arcs (2PA) arrangement in prostate SBRT-VMAT for the same patient.

Average dose-volume histograms of the (A) PTV, (B) bladder, (C) rectum, (D) left femoral head, and (E) right femoral head from prostate SBRT-VMAT plans for four arc arrangements (1FA, 1PA, 2FA, and 2PA).

Dosimetric results for target volumes in prostate SABR-VMAT plans using four arc arrangements.

	Avg ±SD (range)

	1FA	1PA	2FA	2PA
CTV coverage
D_50% (Gy)	44.9±0.4	44.6±0.5	44.5±0.5	44.4±0.3
D_50% (Gy)	(44.4-45.4)	(44.1-45.1)	(44.0-45.3)	(44.0-44.7)
D_5% (Gy)	46.0±0.1	45.9±0.1	45.9±0.1	45.8±0.2
D_5% (Gy)	(45.9-46.1)	(45.7-46.0)	(45.8-46.0)	(45.7-45.9)
D_95% (Gy)	43.5±0.5	43.1±0.4	43.1±0.6	42.8±0.2
D_95% (Gy)	(43.0-44.2)	(42.8-43.5)	(42.6-43.9)	(42.7-43.1)
V_100% (%)	98.4±1.8	97.9±0.0	97.8±3.8	97.6±2.0
V_100% (%)	(95.5-100.0)	(95.0-99.8)	(95.2-100.0)	(94.2-99.9)
PTV coverage
D_mean	44.3±0.2	44.2±0.1	44.1±0.3	44.3±0.1
D_mean	(44.2-44.6)	(44.0-44.4)	(44.0-44.6)	(44.2-44.5)
D_max	48.8±0.8	49.5±0.9	48.5±1.1	49.0±1.4
D_max	(47.8-49.8)	(48.4-50.5)	(47.2-50.0)	(47.4-50.5)
D_min	33.0±0.4	32.3±0.0	32.8±0.8	33.7±0.3
D_min	(32.4-33.2)	(31.9-33.7)	(32.1-33.9)	(33.4-34.1)
D_50% (Gy)	44.6±0.3	44.5±0.2	44.4±0.4	44.5±0.2
D_50% (Gy)	(44.2-45.0)	(44.3-44.8)	(44.1-45.0)	(44.3-44.8)
D_5% (Gy)	46.1±0.2	46.1±0.1	46.1±0.2	46.0±0.1
D_5% (Gy)	(45.9-46.3)	(45.9-46.2)	(45.9-46.3)	(45.9-46.2)
D_95% (Gy)	41.5±0.3	41.4±0.2	41.3±0.3	41.7±0.1
D_95% (Gy)	(41.1-41.8)	(41.2-41.8)	(41.0-41.7)	(41.6-41.9)
V_100% (%)	87.5±1.9	86.6±1.2	87.7±1.5	88.1±1.0
V_100% (%)	(85.1-90.2)	(85.0-87.8)	(85.8-89.3)	(87.1-89.9)
Conformity	1.05±0.00	1.04±0.01	1.03±0.01	1.05±0.01
index	(1.02-1.03)	(1.02-1.04)	(1.02-1.04)	(1.02-1.03)
Conformation	0.91±0.01	0.91±0.01	0.91±0.01	0.91±0.01
number	(0.90-0.92)	(0.09-0.92)	(0.91-0.92)	(0.90-0.93)
Homogeneity	0.10±0.01	0.11±0.00	0.11±0.01	0.10±0.00
index	(0.09-0.12)	(0.10-0.11)	(0.10-0.12)	(0.09-0.10)

Dose volume constraints adopted for planning study.

Volume	Rectum	Bladder	Femoral heads
	V_42.7_{Gy (100%)} < 5%	V_42.7_Gy(100%) < 10%	V_29.9_{Gy (70%)} < 50%
	V_38.4_{Gy (90%)} < 15%	V_34.7_{Gy (81%)} < 25%	D_max <29.9 Gy
Constraints	V_32.0_{Gy (75%)} < 35%	V_{29.9 Gy(70%)} < 50%
	V_28.0_{Gy (65%)} < 45%
	V_{_24.8_{Gy (58%)} < 70%}
	V_20.0_{Gy (47%)} < 80%

Average monitor unit and delivery time for prostate SBRT-VMAT plans using four arc arrangements.

Beams	1FA (Mean ± SD)	1PA (Mean ± SD)	2FA (Mean ± SD)	2PA (Mean ± SD)
MU	1575±63	1627±56	1646±97	1660±98

Delivery time (min)	1.01±0.02	0.69±0.01	2.00±0.01	1.36±0.02

TCP of prostate tumor and NTCP of OARs for four arc arrangement plans.

Beams	1FA (Mean±SD)	1PA (Mean±SD)	2FA (Mean±SD)	2PA (Mean±SD)
TCP (%)
Prostate	93.35±0.08	99.28±0.06	93.32±0.08	93.36±0.08
NTCP (%)
Rectum	0.44±0.23	0.61±0.21	0.40±0.23	0.56±0.22
Bladder	0.01±0.02	0.01±0.03	0.00±0.01	0.00±0.02
LT Femur	0.00±0.00	0.00±0.00	0.00±0.00	0.00±0.00
RT Femur	0.00±0.00	0.00±0.00	0.00±0.00	0.00±0.00

Parameters used to calculated Niemierko’s EUD-based TCP and NTCP.

Tissue	100%dpf (Gy)	Fraction (#)	α	γ₅₀	TD₅₀ (Gy)	TCD₅₀ (Gy)	dpf (Gy)	α/β (Gy)
Prostate	6.1	7	-10	1.0		28.34	2	1.20
Rectum	6.1	7	8.33	4	80		2	3.90
Bladder	6.1	7	2	4	80		2	8.00
Femur	6.1	7	4	4	65		2	0.85

Dosimetric results for organs at risk in prostate SABR-VMAT plans using four arc arrangements.

	Avg SD (range)

	IFA	1PA	2FA	2PA
Organs at risk
Rectum D_mean (Gy)	25.2±1.7	23.3±2.0	23.6±1.8	23.4±1.9
Rectum D_mean (Gy)	(23.1-27.2)	(21.4-25.8)	(21.3-26.0)	(21.3-26.4)
Rectum D_2% (Gy)	44.2±0.3	44.6±0.4	44.1±0.4	44.5±0.2
Rectum D_2% (Gy)	(43.7-44.5)	(44.0-45.1)	(43.8-44.7)	(44.3-44.9)
Rectum V_95% (%)	9.0±1.4	10.1±1.3	8.3±1.3	9.8±1.5
Rectum V_95% (%)	(6.6-10.3)	(8.1-11.5)	(7.0-10.2)	(7.6-11.6)
Rectum V_80% (%)	19.1±3.0	19.7±3.2	18.0±2.8	19.4±3.4
Rectum V_80% (%)	(15.1-23.2)	(15.2-23.8)	(15.2-21.9)	(14.8-24.3)
Rectum V_50% (%)	71.0±8.8	53.9±9.4	60.0±11.1	54.1±9.0
Rectum V_50% (%)	(61.1-80.1)	(41.9-63.7)	(46.9-77.4)	(42.5-66.7)
Rectum V_20% (%)	90.2±2.5	90.0±2.7	89.6±3.0	90.0±2.8
Rectum V_20% (%)	(87.7-93.4)	(87.1-94.1)	(85.6-93.5)	(87.3-94.0)
Bladder D_mean (Gy)	19.0±6.9	18.7±7.1	18.5±6.1	18.3±6.9
Bladder D_mean (Gy)	(13.4-31.1)	(13.2-31.0)	(15.7-29.0)	(12.9-30.4)
Bladder D_2% (Gy)	45.6±0.2	45.6±0.2	45.5±0.3	45.6±0.4
Bladder D_2% (Gy)	(45.5-45.8)	(45.3-45.9)	(45.0-45.8)	(45.3-46.4)
Bladder V_95% (%)	21.2±11.1	21.4±11.1	20.9±10.5	21.4±11.3
Bladder V_95% (%)	(10.5-39.3)	(10.6-39.4)	(10.3-37.7)	(10.7-39.9)
Bladder V_80% (%)	25.6±11.9	26.2±11.9	25.7±11.1	26.0±12.0
Bladder V_80% (%)	(16.6-46.4)	(16.5-46.3)	(16.6-44.6)	(16.3-46.2)
Bladder V_50% (%)	40.4±13.6	38.6±12.6	39.5±12.4	38.2±12.9
Bladder V_50% (%)	(29.4-64.1)	(28.5-60.5)	(29.2-60.7)	(27.5-60.6)
Bladder V_20% (%)	54.4±17.0	52.5±16.1	54.1±17.4	52.1±16.1
Bladder V_20% (%)	(37.2-79.1)	(36.4-76.5)	(37.0-79.4)	(36.2-76.1)
Left femoral head	12.8±1.8	18.7±2.3	12.7±2.4	13.9±1.4
D_mean (Gy)	(10.5-15.1)	(16.9-22.7)	(9.3-14.9)	(11.7-15.3)
Left femoral head	19.7±2.2	23.5±4.4	18.3±3.0	20.1±2.0
D_2% (Gy)	(16.9-21.8)	(15.6-26.1)	(13.4-20.7)	(16.7-21.8)
Right femoral	10.8±0.9	13.3±2.5	12.4±1.7	13.7±2.1
head D_mean (Gy)	(9.2-11.3)	(9.2-15.5)	(10.5-14.2)	(10.7-16.5)
Right femoral	16.4±1.3	20.6±3.7	18.1±1.9	19.7±2.3
head D_2% (Gy)	(14.3-18.0)	(14.3-23.6)	(15.8-20.1)	(16.2-22.5)

eISSN:: 1581-3207
Sprache:: Englisch

Zeitrahmen der Veröffentlichung:: 4 Hefte pro Jahr
Fachgebiete der Zeitschrift:: Medizin, Klinische Medizin, Radiologie, Allgemeinmedizin, Innere Medizin, Hämatologie, Onkologie

Zeitschrift RSS Feed